Eli Lilly Raises Annual Profit Forecast on Accelerated Growth from GLP-1 Drugs

Eli Lilly has revised its annual profit forecast upward, driven by strong sales of its GLP-1 drugs. The company noted that increased demand for these medications, particularly for diabetes and weight loss treatment, has positively impacted its financial performance. Under the new guidance, Eli Lilly's adjusted earnings per share forecast for 2023 has been raised to the upper end of its previous range. This revision reflects the company's leading position in the GLP-1 market and its operational efficiency. The company reported that third-quarter financial results exceeded expectations, with robust sales of products such as Mounjaro and Trulicity. This has attracted investor interest and led to a rise in the stock price. Eli Lilly's strong performance is supported by the expanding applications of GLP-1 drugs and a growing patient base. The company expects this trend to continue in the coming period. This is not investment advice.